Weekly Investment Analysts’ Ratings Updates for Kura Oncology (KURA)

Several brokerages have updated their recommendations and price targets on shares of Kura Oncology (NASDAQ: KURA) in the last few weeks:

• 10/20/2025 – Kura Oncology had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $36.00 price target on the stock.
• 10/20/2025 – Kura Oncology had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $24.00 price target on the stock.
• 10/20/2025 – Kura Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 10/8/2025 – Kura Oncology had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/7/2025 – Kura Oncology was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 9/30/2025 – Kura Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 9/27/2025 – Kura Oncology had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/4/2025 – Kura Oncology is now covered by analysts at Guggenheim. They set a “neutral” rating on the stock.

Insiders Place Their Bets

In related news, insider Mollie Leoni sold 12,314 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $8.94, for a total transaction of $110,087.16. Following the completion of the transaction, the insider owned 158,439 shares of the company’s stock, valued at approximately $1,416,444.66. This represents a 7.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Brian T. Powl sold 8,891 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $79,485.54. Following the transaction, the insider directly owned 99,676 shares of the company’s stock, valued at $891,103.44. This trade represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 78,058 shares of company stock valued at $697,839. 6.40% of the stock is currently owned by insiders.

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.